Ensitrelvir (Xocova) is an antiviral developed by Shionogi. Approvals for preventing or treating the initial infection do not establish a treatment for Long COVID.
Shionogi, the developer · Health Canada, which authorizes specific uses
Stage
Preparing
Sent
Replies
Resolved
Next milestone
LCAC will confirm the responsible Shionogi contact and prepare the first request for review. No contact has been made yet.
Preparing campaignCampaign updated: 8 Oct 2026
Approval for preventing COVID-19 after exposure does not establish a treatment for Long COVID.
Progress and next step
Starting with the evidence and the ask.
No request has been sent. LCAC is confirming the Shionogi contact and preparing two asks: Canadian access plans and support for Long COVID research.
What happens next?
LCAC will review contributions and prepare the first request for review. Once sent, the request and date will be published here, followed by replies and outstanding questions.
Background
What is ensitrelvir, and why seek access?
Ensitrelvir is a medicine taken by mouth that blocks the SARS-CoV-2 main protease, an enzyme the virus needs to make copies of itself. Its brand names include Xocova and Zokovea. Its approved uses vary by country. FDA prescribing information · EMA medicine record.
Canadian access for preventing or treating the initial infection is separate from research into established Long COVID. Neither establishes a proven Long COVID treatment.
Approvals, Canadian records and trial evidence
How does it differ from Paxlovid?
Canada currently has one authorized oral antiviral treatment for COVID-19: Paxlovid. Remdesivir is another authorized antiviral, given intravenously. Eligibility and access depend on local services. Health Canada’s treatment overview.
Paxlovid combines two medicines. Nirmatrelvir blocks the virus’s main protease. Ritonavir slows nirmatrelvir’s breakdown in the body. In Canada, Paxlovid treats acute COVID-19 in eligible adults at high risk of severe illness. Canadian Paxlovid monograph (PDF).
Ensitrelvir targets the same viral enzyme, without ritonavir. It has its own important drug interactions. Both medicines require interaction checks; their approved uses also differ, as explained below. Ensitrelvir prescribing information (PDF).
Prevention, acute treatment and Long COVID are different questions.
Preventing COVID-19 after exposure: the U.S. and EU approved ensitrelvir for post-exposure prevention in people aged 12 and over in 2026. This use aims to prevent symptomatic COVID-19 after contact with someone who has it. It does not prove prevention of Long COVID.
Treating the initial infection: Japan has approved ensitrelvir for acute COVID-19. The U.S. approval is for post-exposure prevention, not acute treatment. Canadian plans need to address each intended use separately. Shionogi’s Japan approval summary.
Treating established Long COVID: the U.S. PREVAIL-LC trial at UCSF has already tested a five-day course in 40 participants. Results were posted in April 2026. These pilot findings do not establish a proven treatment, but must inform any further research request. Read the trial and its results.
Where does Canada stand?
As checked on 8 October 2026, LCAC found no ensitrelvir authorization listing in Health Canada’s Drug Product Database and no entry in the public submissions-under-review or completed lists. Those submission lists were current to 31 August 2026; they cannot rule out a recent filing or a submission still being screened. Drug Product Database · Public submission records.
Why LCAC is involved: Canadians need a clear answer about access plans, and people with Long COVID need research that builds on existing evidence. The first step is to ask Shionogi what it plans to pursue here and what would make further research possible.
Our ask
One campaign. Two separate asks.
Canadian access for prevention or acute treatment, and access for Long COVID research, need different evidence and decisions.
01
A Canadian access pathway. Ask Shionogi to explain whether it has submitted, or plans to submit, ensitrelvir to Health Canada; which indications it would seek; and its anticipated steps, barriers and timing for Canadian supply. Address post-exposure prevention and acute COVID-19 treatment separately.
Request in preparation
02
Support for established Long COVID research. Ask Shionogi to assess collaboration with Canadian investigators, including access to study medication and relevant data. A proposal should address PREVAIL-LC’s findings, its remaining uncertainties, safety, patient involvement and outcomes that matter to patients.
Request in preparation
Ways to help
Help prepare the first request.
Share the campaign, suggest a question, check a source or contribute your expertise. Times are estimates; a brief or partial contribution is welcome. Joining LCAC is not required.
Public emails to institutions will be considered once the recipient and request are clear. For now, these actions help LCAC prepare that request.
Evidence
What the request needs to address.
01
Benefits depend on the use studied. SCORPIO-PEP found fewer symptomatic infections after household exposure. That outcome does not establish benefit for established Long COVID. Primary trial results.
Post-exposure prevention
02
Existing Long COVID research comes first. PREVAIL-LC is a small pilot with posted outcome estimates and no reported between-group statistical analyses in the registry results. LCAC’s request should ask what those findings justify studying next, rather than assume treatment works. PREVAIL-LC results.
Established Long COVID
03
Acute treatment results are mixed. SCORPIO-HR did not significantly improve its primary symptom-resolution outcome despite antiviral activity. Research aimed at preventing later Long COVID after acute infection answers a different question from treating illness that is already established. SCORPIO-HR results · RESILIENCE protocol.
Acute infection
04
Access and study design must include safety. Ensitrelvir has important drug interactions and pregnancy-related risks. Any access or research proposal must address the relevant safeguards. FDA safety information.
Safety and eligibility
Who can act
Different roles in access and research.
Shionogi: can explain its Canadian submission and supply plans, identify the responsible team and assess research collaboration. LCAC will confirm the appropriate route through Shionogi Canada.
Health Canada: reviews submissions for safety, efficacy and quality, and authorizes specific uses when the requirements are met. Approval and actual supply are separate steps. How Canadian drug review works.
Canadian investigators and research partners: would need to develop an appropriate study, secure funding and approvals, and involve patients in its design. No Canadian study or partnership is being announced here.
Drafts and review tasks
An evidence-review task.
Check one access or research question and send LCAC a short, sourced note.
Show 1 item
Evidence-review task
Choose one question to check.
You do not need to review the whole campaign. A short note with a source and the date you checked it is enough.
Canadian access: check the Drug Product Database or public submission lists for ensitrelvir, Xocova or Zokovea. Note the record’s date and what it establishes. An absent public entry cannot prove there has been no recent filing.
Established Long COVID research: read PREVAIL-LC’s design and posted results. Identify one limitation or unanswered question that a Canadian research proposal should address.
Send three to five bullets: what you checked, the primary source, what is known and one question for Shionogi. LCAC will verify notes before using them; contribution does not guarantee inclusion or publication. No personal medical history is needed.
